Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
Executive Summary
FDA's release of Centocor from a Risk Evaluation and Mitigation Strategy for Simponi could signal a reprieve from the REMS regulatory burden for other tumor necrosis factor inhibitors as well.
You may also be interested in...
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
FDA should take no more than three months deciding whether a Medication Guide can be pulled out of an existing Risk Evaluation and Mitigation Strategy, the Pharmaceutical Research and Manufacturers of America believes.
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
FDA should take no more than three months deciding whether a Medication Guide can be pulled out of an existing Risk Evaluation and Mitigation Strategy, the Pharmaceutical Research and Manufacturers of America believes.
FDA Warns Again Of Rare Cancer Associated With TNF Blockers
FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.